What key role can CDK2 antibodies play in tumor research?

1. What role does CDK2 play in cell cycle regulation?

Cyclin-dependent kinase 2 (CDK2) is a key molecule in regulating cell cycle progression, primarily functioning during the S and M phases of the cell cycle. Under normal physiological conditions, CDK2 forms a complex with cyclin E, phosphorylating the retinoblastoma protein (Rb) to promote cell passage through the G1/S checkpoint and initiate DNA replication. Upon entering the S phase, CDK2 binds to cyclin A and phosphorylates the E2F transcription factor, inactivating it to prevent abnormal activation of apoptosis and ensuring smooth DNA replication. This precise regulation allows cells to complete the division cycle in an orderly manner. Although studies show that CDK2 is not essential for normal development in most tissues, its abnormal activation in tumorigenesis has garnered significant attention.

2. How is abnormal CDK2 activation associated with tumorigenesis?

Multiple studies have confirmed that abnormal activation of CDK2 is closely linked to the development and progression of various malignancies. Abnormal activation of the CDK2 signaling pathway has been observed in numerous tumor types, including ovarian cancer, neuroblastoma, and non-small cell lung cancer. Specific tumor subtypes, such as CCNE1-amplified ovarian cancer, MYCN-amplified neuroblastoma, and KRAS-mutated lung cancer, exhibit strong dependence on CDK2, which is crucial for their growth and proliferation. This tumor-selective dependence makes CDK2 a potential anti-tumor therapeutic target, and the development of research antibodies provides essential tools for exploring this target.

3. What are the key applications of CDK2 antibodies in basic research?

CDK2-specific antibodies have multiple applications in studying CDK2 function and tumor mechanisms:

1. Protein Expression and Localization Analysis: Using techniques such as immunohistochemistry and immunofluorescence, CDK2 antibodies can detect CDK2 expression levels and subcellular localization in different tissues and tumors.

2. Protein Interaction Studies: Through co-immunoprecipitation, CDK2 antibodies can capture protein complexes interacting with CDK2, such as cyclins and substrate proteins, to analyze CDK2's functional network.

3. Phosphorylation State Analysis: Developing CDK2 antibodies targeting specific phosphorylation sites enables the study of CDK2 activation states and their dynamic changes during different cell cycle phases.

4. Clinical Sample Analysis: By detecting CDK2 expression in tumor tissue samples, correlations between CDK2 expression levels and clinical prognosis can be established, providing a basis for patient stratification.

4. What technical challenges does CDK2 antibody development face?

The development and application of CDK2 antibodies face multiple technical challenges:

1. Homology Challenge: CDK2 shares up to 74% amino acid sequence similarity with other family members like CDK3, making the development of highly specific antibodies technically difficult. Precise epitope design is required to distinguish between highly similar family members.

2. Conformational Dynamics: CDK2 undergoes significant conformational changes when binding to different cyclins, requiring detailed structural information to guide the development of antibodies that recognize specific functional states.

3. Post-Translational Modifications: CDK2 activity is regulated by various post-translational modifications, such as phosphorylation and acetylation, making the development of functional antibodies that recognize specific modification states highly challenging.

4. Clinical Translation: For clinical sample detection, technical issues such as antibody sensitivity, specificity, and quantitative standardization in fixed tissues must be addressed.

5. What biological challenges does CDK2-targeted therapy face?

Although CDK2 is a potential anti-tumor target, its targeted therapy still faces significant biological challenges:

1. Tissue-Selective Toxicity: While most normal tissues have low dependence on CDK2, certain highly proliferative tissues like the testes express high levels of CDK2, potentially leading to toxic effects such as infertility with CDK2 inhibitors.

2. Compensatory Mechanisms: Studies show that inhibiting CDK2 may trigger compensatory activation of other CDK family members, such as CDK1 or CDK4/6, to maintain tumor cell proliferation, significantly impacting antibody therapeutic efficacy.

3. Drug Resistance Development: Tumor cells may evade CDK2 inhibition by upregulating alternative signaling pathways or mutating target proteins, necessitating in-depth research into resistance mechanisms.

4. Therapeutic Window Optimization: Balancing therapeutic effects with potential toxicity requires a deep understanding of CDK2 function to identify the optimal treatment window.

6. What are the future research directions for CDK2 antibodies?

Research antibodies targeting CDK2 will continue to play a crucial role in the following areas:

1. Diagnostic Biomarker Development: Using CDK2 antibodies to establish standardized detection methods for CDK2 expression levels, identifying patient populations likely to benefit from CDK2-targeted therapies.

2. Combination Therapy Research: Studying the synergistic effects of CDK2 antibodies with other targeted drugs, such as CDK4/6 inhibitors, BCL-2 inhibitors, and BRD4 inhibitors, to explore more effective combination treatment strategies.

3. Resistance Mechanism Analysis: Using CDK2 antibodies to study dynamic changes in the CDK2 signaling pathway during resistance development, elucidating compensatory mechanisms and resistance pathways.

4. Therapeutic Response Monitoring: Developing CDK2 antibody-based systems to monitor treatment responses in real-time, assessing the impact of CDK2 inhibitors on tumor cells.

7. Which manufacturers provide CDK2 antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "CDK2 Recombinant Rabbit Monoclonal Antibody (CDK2 Recombinant Rabbit mAb (SDT-064-40))" (Catalog No.: S0B2152), a key tool for cell cycle research with high specificity, high affinity, and excellent stability. This product was developed using the company's S-RMab® recombinant rabbit monoclonal antibody platform technology, enabling high-specificity recognition of CDK2 proteins across multiple species, including human, mouse, and rat. It performs exceptionally well in applications such as Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP), making it an ideal choice for cell cycle regulation, tumorigenesis mechanism research, and targeted drug development.

Professional Technical Support: We provide detailed validation data packages for this antibody, including species cross-reactivity validation, optimized protocols for various application conditions, and representative result images. Our technical team offers tailored application consultations to help overcome technical challenges in your research.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-value antibody tools and solutions for cell biology, oncology, and innovative drug development. For more information about the "CDK2 Recombinant Rabbit Monoclonal Antibody" (Catalog No. S0B2152), to access validation data, or to request sample testing, please feel free to contact us.

Product Information